Expression of p53 and p16 in Carcinoma Breast Tissue: Depicts Prognostic Significance or Coincidence

Abstract

Breast cancer remains the most common malignancy among the Indian female population. The p16 and p53 genes are frequently mutated in breast cancer. Therefore, we aimed to evaluate the prognostic significance of p16 and p53 overexpression in breast cancer and their correlation with various traditional prognostic parameters. Total of 100 confirmed cases of breast cancers were selected. Patients who underwent chemotherapy treatment were excluded from the study. Estrogen receptor (ER), progesterone receptor (PR), and Her2neu immunohistochemistry were performed. The p16 and p53 immunohistochemistry was performed on all cases and association with various clinicopathologic parameters was determined. The mean age of carcinoma breast was 53.3+11.6 with age ranging from 28 to 82 years. On histopathological examination, 93% of cases were of invasive ductal cell carcinoma (IDC) with majority of grade I (43%). Only 14% of cases showed positive p53 expression and 19% of cases showed positive p16 expression. P16 was seen in a very significant correlation with p53 expression in all breast carcinoma cases (<0.002). p53 expression showed a positively significant (<0.05) correlation with age and grade III. The p16 expression was seen significantly correlated with low mitotic activity index (MAI) only. The p53 over-expression was seen in worse prognostic factors such as high tumor grade, Her2neu and triple-negative expression suggested its potential role in pathogenesis of carcinoma breast. In addition, high expression of p16 seen in low mitotic count and Her2neu expression also emphasized the role of this biomarker and recommends further molecular-based research.

Significance of RCC2, Rac1 and p53 Expression in Breast Infiltrating Ductal Carcinoma; An Immunohistochemical Study

“…Additionally, p53 expression percent showed a significant positive linear correlation with frequent apoptosis, and mild p53 intensity showed a significant relation with advanced nodal stage (N2+N3). Previous studies have declared the association of p53 with poor prognostic parameters including high tumor grade, high Ki-67 proliferation index, Her2neu, and triple-negative expression (41, [45][46][47]. However, it was reported that the p53 mutation did not impact the outcome of breast cancer (48).…”

Disposable paper-based screen-printed electrochemical immunoplatform for dual detection of esophageal cancer biomarkers in patients' serum samples

“…13 It is a gene that acts as a tumor suppressor biomarker, thus playing a vital part in controlling cell proliferation, genetic stability, and regulating cell growth. 14 When a gene mutation occurs in >50% of all cancers owing to its transformed spatial conformation, 15 such as liver cancer, 16 breast cancer, 17 esophageal cancer, 18 and lung cancer, the ability of TP53 to regulate cells is lost. Consequently, the detection of these protein cancerous biomarkers in various matrices could be used to monitor different human cancers.…”

To compare the expression of p53 with hormonal receptor status in breast carcinoma: An immunohistochemical study

“…Screening detects some cancers before they have metastasized, hence by using screening methods such as ultrasound and mammography, conducting self-examination, the age of breast cancer incidence has reduced in the last few years [2] . However, reappearance may be seen in 20%-30% of breast cancer patients despite the employment of the effective therapies based on presented prognostic factors [3] . Tumor markers are molecules occurring in tissues that are associated with cancer.…”